Natural and Synthetic Cannabinoids: Pharmacology, Uses, Adverse Drug Events, and Drug Interactions

The purpose of this narrative review is to describe the current use environment of both natural and synthetic cannabinoids while providing context for cannabinoid chemistry and pharmacology. In addition to a long history of recreational and nonmedical use, natural cannabinoids are increasingly used...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical pharmacology 2021-08, Vol.61 (S2), p.S37-S52
Hauptverfasser: Brown, Joshua D., Rivera Rivera, Kevin J., Hernandez, Leilanie Y. Crespo, Doenges, Matthew R., Auchey, India, Pham, Thanh, Goodin, Amie J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page S52
container_issue S2
container_start_page S37
container_title Journal of clinical pharmacology
container_volume 61
creator Brown, Joshua D.
Rivera Rivera, Kevin J.
Hernandez, Leilanie Y. Crespo
Doenges, Matthew R.
Auchey, India
Pham, Thanh
Goodin, Amie J.
description The purpose of this narrative review is to describe the current use environment of both natural and synthetic cannabinoids while providing context for cannabinoid chemistry and pharmacology. In addition to a long history of recreational and nonmedical use, natural cannabinoids are increasingly used as prescription products, through medical cannabis programs, and as consumer health products. Despite anecdotal safety evidence, cannabis and cannabinoids are pharmacologically complex and pose risks for adverse drug events and drug‐drug interactions. Synthetic cannabinoids, particularly agonists of cannabinoid receptors, are more potent than natural cannabinoids and can lead to more severe reactions and medical emergencies. This review provides a summary of approved uses and an overview of mechanisms of action for adverse drug events with natural and synthetic cannabinoids. Clinical considerations for special populations that may be at heightened risk for drug‐drug interactions and adverse drug events while using natural or synthetic cannabinoids are examined, and recommendations are provided.
doi_str_mv 10.1002/jcph.1871
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_wiley_primary_10_1002_jcph_1871_JCPH1871</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2561347345</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3881-39411ffa4f234850fc18c3c8a659039c9d9bd173edaf5b2d887cb97a0cc4beb23</originalsourceid><addsrcrecordid>eNp1kEFLwzAYhoMobk4P_gEpeFFYt6RJ2sTbqNNNhg5055Km6dbRpTNpJ_33ttv0IHj64OXh4eMB4BrBAYLQG67ldjVALEAnoIso9VziQ3IKuhBy5HoBhB1wYe0aQuQTis5BBxPMfUpZF8SvoqyMyB2hE-e91uVKlZl0QqG1iDNdZIl9cOYrYTZCFnmxrPvOwirbd0bJThmrnEdTLZ3xTumyGVvJfpjqUhkhy6zQ9hKcpSK36up4e2DxNP4IJ-7s7XkajmauxIwhF3OCUJoKknqYMApTiZjEkgmfcoi55AmPExRglYiUxl7CWCBjHggoJYlV7OEeuDt4t6b4rJQto01mpcpzoVVR2cijPuJeU4A16O0fdF1URjff7SlMAkxoQ90fKGkKa41Ko63JNsLUEYJRGz5qw0dt-Ia9ORqreKOSX_KndAMMD8BXlqv6f1P0Es4ne-U3j4eMrQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2561347345</pqid></control><display><type>article</type><title>Natural and Synthetic Cannabinoids: Pharmacology, Uses, Adverse Drug Events, and Drug Interactions</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Brown, Joshua D. ; Rivera Rivera, Kevin J. ; Hernandez, Leilanie Y. Crespo ; Doenges, Matthew R. ; Auchey, India ; Pham, Thanh ; Goodin, Amie J.</creator><creatorcontrib>Brown, Joshua D. ; Rivera Rivera, Kevin J. ; Hernandez, Leilanie Y. Crespo ; Doenges, Matthew R. ; Auchey, India ; Pham, Thanh ; Goodin, Amie J.</creatorcontrib><description>The purpose of this narrative review is to describe the current use environment of both natural and synthetic cannabinoids while providing context for cannabinoid chemistry and pharmacology. In addition to a long history of recreational and nonmedical use, natural cannabinoids are increasingly used as prescription products, through medical cannabis programs, and as consumer health products. Despite anecdotal safety evidence, cannabis and cannabinoids are pharmacologically complex and pose risks for adverse drug events and drug‐drug interactions. Synthetic cannabinoids, particularly agonists of cannabinoid receptors, are more potent than natural cannabinoids and can lead to more severe reactions and medical emergencies. This review provides a summary of approved uses and an overview of mechanisms of action for adverse drug events with natural and synthetic cannabinoids. Clinical considerations for special populations that may be at heightened risk for drug‐drug interactions and adverse drug events while using natural or synthetic cannabinoids are examined, and recommendations are provided.</description><identifier>ISSN: 0091-2700</identifier><identifier>EISSN: 1552-4604</identifier><identifier>DOI: 10.1002/jcph.1871</identifier><identifier>PMID: 34396558</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>adverse drug events ; Age Factors ; cannabinoid pharmacology ; Cannabinoid Receptor Agonists - metabolism ; Cannabinoid receptors ; cannabinoids ; Cannabinoids - adverse effects ; Cannabinoids - chemistry ; Cannabinoids - pharmacology ; Cannabis ; Drug and Narcotic Control - organization &amp; administration ; Drug Interactions ; drug‐drug interactions ; Endocannabinoids - metabolism ; Female ; Humans ; Medical Marijuana - pharmacology ; Medical Marijuana - therapeutic use ; Pharmacists ; Pregnancy ; Prenatal Exposure Delayed Effects - epidemiology ; Prenatal Exposure Delayed Effects - pathology ; synthetic cannabinoids ; United States</subject><ispartof>Journal of clinical pharmacology, 2021-08, Vol.61 (S2), p.S37-S52</ispartof><rights>2021, The American College of Clinical Pharmacology</rights><rights>2021, The American College of Clinical Pharmacology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3881-39411ffa4f234850fc18c3c8a659039c9d9bd173edaf5b2d887cb97a0cc4beb23</citedby><cites>FETCH-LOGICAL-c3881-39411ffa4f234850fc18c3c8a659039c9d9bd173edaf5b2d887cb97a0cc4beb23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjcph.1871$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjcph.1871$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,27926,27927,45576,45577</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34396558$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brown, Joshua D.</creatorcontrib><creatorcontrib>Rivera Rivera, Kevin J.</creatorcontrib><creatorcontrib>Hernandez, Leilanie Y. Crespo</creatorcontrib><creatorcontrib>Doenges, Matthew R.</creatorcontrib><creatorcontrib>Auchey, India</creatorcontrib><creatorcontrib>Pham, Thanh</creatorcontrib><creatorcontrib>Goodin, Amie J.</creatorcontrib><title>Natural and Synthetic Cannabinoids: Pharmacology, Uses, Adverse Drug Events, and Drug Interactions</title><title>Journal of clinical pharmacology</title><addtitle>J Clin Pharmacol</addtitle><description>The purpose of this narrative review is to describe the current use environment of both natural and synthetic cannabinoids while providing context for cannabinoid chemistry and pharmacology. In addition to a long history of recreational and nonmedical use, natural cannabinoids are increasingly used as prescription products, through medical cannabis programs, and as consumer health products. Despite anecdotal safety evidence, cannabis and cannabinoids are pharmacologically complex and pose risks for adverse drug events and drug‐drug interactions. Synthetic cannabinoids, particularly agonists of cannabinoid receptors, are more potent than natural cannabinoids and can lead to more severe reactions and medical emergencies. This review provides a summary of approved uses and an overview of mechanisms of action for adverse drug events with natural and synthetic cannabinoids. Clinical considerations for special populations that may be at heightened risk for drug‐drug interactions and adverse drug events while using natural or synthetic cannabinoids are examined, and recommendations are provided.</description><subject>adverse drug events</subject><subject>Age Factors</subject><subject>cannabinoid pharmacology</subject><subject>Cannabinoid Receptor Agonists - metabolism</subject><subject>Cannabinoid receptors</subject><subject>cannabinoids</subject><subject>Cannabinoids - adverse effects</subject><subject>Cannabinoids - chemistry</subject><subject>Cannabinoids - pharmacology</subject><subject>Cannabis</subject><subject>Drug and Narcotic Control - organization &amp; administration</subject><subject>Drug Interactions</subject><subject>drug‐drug interactions</subject><subject>Endocannabinoids - metabolism</subject><subject>Female</subject><subject>Humans</subject><subject>Medical Marijuana - pharmacology</subject><subject>Medical Marijuana - therapeutic use</subject><subject>Pharmacists</subject><subject>Pregnancy</subject><subject>Prenatal Exposure Delayed Effects - epidemiology</subject><subject>Prenatal Exposure Delayed Effects - pathology</subject><subject>synthetic cannabinoids</subject><subject>United States</subject><issn>0091-2700</issn><issn>1552-4604</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kEFLwzAYhoMobk4P_gEpeFFYt6RJ2sTbqNNNhg5055Km6dbRpTNpJ_33ttv0IHj64OXh4eMB4BrBAYLQG67ldjVALEAnoIso9VziQ3IKuhBy5HoBhB1wYe0aQuQTis5BBxPMfUpZF8SvoqyMyB2hE-e91uVKlZl0QqG1iDNdZIl9cOYrYTZCFnmxrPvOwirbd0bJThmrnEdTLZ3xTumyGVvJfpjqUhkhy6zQ9hKcpSK36up4e2DxNP4IJ-7s7XkajmauxIwhF3OCUJoKknqYMApTiZjEkgmfcoi55AmPExRglYiUxl7CWCBjHggoJYlV7OEeuDt4t6b4rJQto01mpcpzoVVR2cijPuJeU4A16O0fdF1URjff7SlMAkxoQ90fKGkKa41Ko63JNsLUEYJRGz5qw0dt-Ia9ORqreKOSX_KndAMMD8BXlqv6f1P0Es4ne-U3j4eMrQ</recordid><startdate>202108</startdate><enddate>202108</enddate><creator>Brown, Joshua D.</creator><creator>Rivera Rivera, Kevin J.</creator><creator>Hernandez, Leilanie Y. Crespo</creator><creator>Doenges, Matthew R.</creator><creator>Auchey, India</creator><creator>Pham, Thanh</creator><creator>Goodin, Amie J.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>202108</creationdate><title>Natural and Synthetic Cannabinoids: Pharmacology, Uses, Adverse Drug Events, and Drug Interactions</title><author>Brown, Joshua D. ; Rivera Rivera, Kevin J. ; Hernandez, Leilanie Y. Crespo ; Doenges, Matthew R. ; Auchey, India ; Pham, Thanh ; Goodin, Amie J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3881-39411ffa4f234850fc18c3c8a659039c9d9bd173edaf5b2d887cb97a0cc4beb23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>adverse drug events</topic><topic>Age Factors</topic><topic>cannabinoid pharmacology</topic><topic>Cannabinoid Receptor Agonists - metabolism</topic><topic>Cannabinoid receptors</topic><topic>cannabinoids</topic><topic>Cannabinoids - adverse effects</topic><topic>Cannabinoids - chemistry</topic><topic>Cannabinoids - pharmacology</topic><topic>Cannabis</topic><topic>Drug and Narcotic Control - organization &amp; administration</topic><topic>Drug Interactions</topic><topic>drug‐drug interactions</topic><topic>Endocannabinoids - metabolism</topic><topic>Female</topic><topic>Humans</topic><topic>Medical Marijuana - pharmacology</topic><topic>Medical Marijuana - therapeutic use</topic><topic>Pharmacists</topic><topic>Pregnancy</topic><topic>Prenatal Exposure Delayed Effects - epidemiology</topic><topic>Prenatal Exposure Delayed Effects - pathology</topic><topic>synthetic cannabinoids</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brown, Joshua D.</creatorcontrib><creatorcontrib>Rivera Rivera, Kevin J.</creatorcontrib><creatorcontrib>Hernandez, Leilanie Y. Crespo</creatorcontrib><creatorcontrib>Doenges, Matthew R.</creatorcontrib><creatorcontrib>Auchey, India</creatorcontrib><creatorcontrib>Pham, Thanh</creatorcontrib><creatorcontrib>Goodin, Amie J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brown, Joshua D.</au><au>Rivera Rivera, Kevin J.</au><au>Hernandez, Leilanie Y. Crespo</au><au>Doenges, Matthew R.</au><au>Auchey, India</au><au>Pham, Thanh</au><au>Goodin, Amie J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Natural and Synthetic Cannabinoids: Pharmacology, Uses, Adverse Drug Events, and Drug Interactions</atitle><jtitle>Journal of clinical pharmacology</jtitle><addtitle>J Clin Pharmacol</addtitle><date>2021-08</date><risdate>2021</risdate><volume>61</volume><issue>S2</issue><spage>S37</spage><epage>S52</epage><pages>S37-S52</pages><issn>0091-2700</issn><eissn>1552-4604</eissn><abstract>The purpose of this narrative review is to describe the current use environment of both natural and synthetic cannabinoids while providing context for cannabinoid chemistry and pharmacology. In addition to a long history of recreational and nonmedical use, natural cannabinoids are increasingly used as prescription products, through medical cannabis programs, and as consumer health products. Despite anecdotal safety evidence, cannabis and cannabinoids are pharmacologically complex and pose risks for adverse drug events and drug‐drug interactions. Synthetic cannabinoids, particularly agonists of cannabinoid receptors, are more potent than natural cannabinoids and can lead to more severe reactions and medical emergencies. This review provides a summary of approved uses and an overview of mechanisms of action for adverse drug events with natural and synthetic cannabinoids. Clinical considerations for special populations that may be at heightened risk for drug‐drug interactions and adverse drug events while using natural or synthetic cannabinoids are examined, and recommendations are provided.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>34396558</pmid><doi>10.1002/jcph.1871</doi><tpages>16</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0091-2700
ispartof Journal of clinical pharmacology, 2021-08, Vol.61 (S2), p.S37-S52
issn 0091-2700
1552-4604
language eng
recordid cdi_wiley_primary_10_1002_jcph_1871_JCPH1871
source MEDLINE; Access via Wiley Online Library
subjects adverse drug events
Age Factors
cannabinoid pharmacology
Cannabinoid Receptor Agonists - metabolism
Cannabinoid receptors
cannabinoids
Cannabinoids - adverse effects
Cannabinoids - chemistry
Cannabinoids - pharmacology
Cannabis
Drug and Narcotic Control - organization & administration
Drug Interactions
drug‐drug interactions
Endocannabinoids - metabolism
Female
Humans
Medical Marijuana - pharmacology
Medical Marijuana - therapeutic use
Pharmacists
Pregnancy
Prenatal Exposure Delayed Effects - epidemiology
Prenatal Exposure Delayed Effects - pathology
synthetic cannabinoids
United States
title Natural and Synthetic Cannabinoids: Pharmacology, Uses, Adverse Drug Events, and Drug Interactions
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T01%3A23%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Natural%20and%20Synthetic%20Cannabinoids:%20Pharmacology,%20Uses,%20Adverse%20Drug%20Events,%20and%20Drug%20Interactions&rft.jtitle=Journal%20of%20clinical%20pharmacology&rft.au=Brown,%20Joshua%20D.&rft.date=2021-08&rft.volume=61&rft.issue=S2&rft.spage=S37&rft.epage=S52&rft.pages=S37-S52&rft.issn=0091-2700&rft.eissn=1552-4604&rft_id=info:doi/10.1002/jcph.1871&rft_dat=%3Cproquest_cross%3E2561347345%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2561347345&rft_id=info:pmid/34396558&rfr_iscdi=true